



Journal of the British Thoracic Society

Impact Factor: 8.121

Editors-in-Chief

N Hart (UK)
G Jenkins (UK)
AR Smyth (UK)

Deputy Editors

N Kaminski (USA)
M Rosenfeld (USA)

Associate Editors

D Baldwin (UK)	J-L Pepin (France)
R Chambers (UK)	M Polkey (UK)
T Coleman (UK)	J Quint (UK)
GJ Criner (USA)	N Rahman (UK)
J Davies (UK)	K Robinson (USA)
A Floto (UK)	S Shaheen (UK)
M Griffiths (UK)	R Stevens (USA)
L Heaney (UK)	A Vonk Noordegraaf (The Netherlands)
N Hopkinson (UK)	C Wainwright (Australia)
S Janes (UK)	T Wilkinson (UK)
B Kampman (UK)	P Wolters (USA)
B Mokhelesi (USA)	
P O'Byrne (Canada)	

Statistical Editors

A Douiri (UK)
C Flach (UK)
C Jackson (UK)
S Stanojevic (USA)
R Szczesniak (USA)
B Wagner (USA)
Y Wang (UK)

Journal Club Editor

J Quint (UK)

President, British Thoracic Society

E Chilvers

Editorial Office

Thorax, BMA House, Tavistock Square,
London WC1H 9JR, UK
T: +44 (0)20 7383 6373
E: thorax@bmj.com

Twitter: @ThoraxBMJ

ISSN: 0040-6376 (print)
ISSN: 1468-3296 (online)

Disclaimer: Thorax is owned and published by the British Thoracic Society and BMJ Publishing Group Ltd, a wholly owned subsidiary of the British Medical Association. The owners grant editorial freedom to the Editor of Thorax.

Thorax follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

Thorax is intended for medical professionals and is provided without warranty, express or implied. Statements in the Journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group Ltd, the British Thoracic Society or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group Ltd shall not be liable for any loss, injury or damage resulting from the use of Thorax or any information in it whether based on contract, tort or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2017 BMJ Publishing Group Ltd and the British Thoracic Society. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior permission of Thorax.

Thorax is published by BMJ Publishing Group Ltd, typeset by Nova Techset Private Limited, Bengaluru & Chennai, India and printed in the UK on acid-free paper.

Thorax (ISSN No: 0040-6376) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431. POSTMASTER: send address changes to Thorax, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

Abbreviations and symbols used in this guideline

Executive summary

Summary of recommendations

- i2 Table 1 Critical illness requiring high levels of supplemental oxygen
- i4 Table 2 Serious illnesses requiring moderate level of supplemental oxygen if the patient is hypoxaemic
- i4 Table 3 Conditions for which patients should be monitored closely but oxygen therapy is not required unless the patient is hypoxaemic
- i5 Table 4 COPD and other conditions requiring controlled or low-dose oxygen therapy
- i11 Table 5 Abbreviations for oxygen devices for use on bedside charts.
- i3 Figure 1 Chart 1—oxygen prescription guidance for acutely hypoxaemic patients in hospital
- i6 Figure 2 Chart 2—flow chart for oxygen administration on general wards in hospitals

Section 1: Introduction

- i14 1.1 Aim of the guideline
- i14 1.2 Intended users of the guideline and target patient populations
- i14 1.3 Areas covered by the guideline
- i14 1.4 Areas not covered by the guideline
- i14 1.5 Key changes since the 2008 guideline
- i15 1.6 Limitations of the guideline

Section 2: Methodology of guideline production

- i15 2.1 Establishment of guideline team
- i15 2.2 Summary of key questions
- i16 2.3 How the evidence was assimilated into the guideline
- i16 2.4 Piloting, implementing and auditing the guideline
- i17 2.5 Planned review and updating of the guideline
- i17 2.6 Declarations of interest
- i15 Table 6 SIGN levels of evidence
- i15 Table 7 SIGN grades of recommendation

Section 3: Normal values and definitions

- i17 3.1 Blood gas levels of oxygen and carbon dioxide in health and disease
 - i17 3.1.1 Normal ranges for oxygen saturation (SaO₂ and SpO₂) and PO₂ (PaO₂) in the blood at sea level
 - i17 3.1.2 Oxygen saturation in older adults
 - i18 3.1.3 Oxygen saturation at altitude
 - i18 3.1.4 Oxygen saturation in acute and chronic diseases
 - i18 3.1.5 Variation in oxygen saturation during sleep
 - i19 3.1.6 Normal range for arterial carbon dioxide tension

- i19 3.2 Definitions of hypoxaemia, hypoxia, type 1 respiratory failure and hyperoxaemia
- i19 3.3 Definition of hypercapnia and type 2 respiratory failure
- i19 3.4 Definition of acidosis (respiratory acidosis and metabolic acidosis)
- i17 Table 8 Mean (SD) PaO₂ (kPa and mmHg) and SaO₂ (%) values (with range)
- i17 Table 9 Ranges, mean, SD, median and IQR values for SpO₂ (%) where measurements were made with the patient receiving air for age ≥18 years (n=37 299) from Smith et al

Section 4: General blood gas physiology

- i20 4.1 Oxygen physiology
- i20 4.2 Carbon dioxide physiology
- i21 4.3 Concept of target oxygen saturation (SaO₂) ranges

Section 5: Advanced blood gas physiology

- i21 5.1 Oxygen delivery
 - i22 5.1.1 Arterial oxygen tension
 - i23 5.1.2 Haematocrit
 - i23 5.1.3 The oxyhaemoglobin dissociation curve and the Bohr effect
 - i23 5.1.4 Regulation of DO₂
- i23 5.2 Pathophysiology of hypoxia and hyperoxia
 - i23 5.2.1 Hypoxaemic hypoxia
 - i24 5.2.2 Other mechanisms of hypoxia
 - i24 5.2.3 Hyperoxia
- i24 5.3 Physiology of carbon dioxide
 - i24 5.3.1 Normal carbon dioxide homeostasis
 - i24 5.3.2 Regulation of carbon dioxide
- i24 5.4 Pathophysiology of hypercapnia and hypocapnia
 - i24 5.4.1 Mechanisms of hypercapnia
 - i25 5.4.2 Hypoventilation and hyperventilation
- i25 5.5 Physiology of oxygen therapy
- i25 5.6 Strategies for improving oxygenation and delivery

MORE CONTENTS ►



This article has been chosen by the Editors to be of special interest or importance and is freely available online.



This article has been made freely available online under the BMJ Journals Open Access scheme. See <http://authors.bmj.com/open-access/>



This journal is a member of and subscribes to the principles of the Committee on Publication Ethics <http://publicationethics.org/>



- i25 5.6.1 Optimising PaO₂
- i26 5.6.2 Optimising oxygen carriage
- i26 5.6.3 Optimising delivery
- i22 Figure 3 Regulation of CaO₂
- i22 Figure 4 Ventilatory response to hypoxaemia
- i23 Figure 5 Oxygen dissociation curve with Bohr effect
- i24 Figure 6 Total carbon dioxide dissociation curve
- i24 Figure 7 Effect of PaCO₂
- i23 Table 10 Approximate relationship between SaO₂ and PaO₂

Section 6: Hypoxia, hypoxaemia, hyperoxaemia, hypercapnia and the rationale of targeted oxygen therapy

- i26 6.1 Effects and risks of hypoxia/hypoxaemia and rationale for target oxygen saturation range
- i27 6.1.1 Desirable oxygen saturation ranges in acute illness
- i28 6.2 Potential benefits of hyperoxaemia and supplemental oxygen therapy in non-hypoxaemic patients
- i28 6.2.1 Hyperoxaemia has been shown to be beneficial in the following situations
- i28 6.2.2 Other potential benefits and potential harms of oxygen therapy in non-hypoxaemic patients
- i28 6.3 Potential adverse physiological effects and clinical risks of supplemental oxygen therapy and hyperoxaemia
- i28 6.3.1 Respiratory system
- i29 6.3.2 Rebound hypoxaemia following sudden cessation of supplementary oxygen therapy
- i29 6.3.3 Cardiovascular and cerebrovascular system
- i29 6.3.4 Reactive oxygen species, tissue toxicity and reports of increased mortality
- i30 6.3.5 Delay in recognition of physiological deterioration
- i30 6.3.6 Acute lung injury in patients with acute paraquat poisoning, bleomycin lung injury and acid aspiration
- i30 6.3.7 Summary of risks of hyperoxaemia and supplemental oxygen therapy
- i30 6.4 Risks of hypercapnia (and respiratory acidosis)
- i31 6.4.1 Effects of a raised blood carbon dioxide level
- i31 6.4.2 Clinical signs
- i31 6.5 Risks of acidosis
- i31 6.6 Rationale of oxygen therapy
- i31 6.7 Target oxygen saturation in acute illness
- i32 6.8 Effects of body positioning including restraint systems
- i26 Table 11 Physiological effects of acute hypoxaemia and hyperoxaemia

Section 7: Clinical and laboratory assessment of hypoxaemia and hypercapnia

- i33 7.1 Assessment of hypoxaemia
- i33 7.1.1 Clinical assessment of breathless patients and assessment of cyanosis
- i34 7.1.2 Value and limitation pulse oximetry
- i36 7.1.3 Arterial and arterialised blood gases
- i36 7.1.4 Transcutaneous oxygen assessment
- i36 7.2 Assessment of hypercapnia and acidosis
- i36 7.2.1 Clinical assessment
- i37 7.2.2 Blood arterial and arteriolar gases
- i37 7.2.3 Venous PCO₂ sampling
- i37 7.2.4 Carbon dioxide monitors and non-invasive assessments of hypercapnia

Section 8: Emergency oxygen use in hospital settings

- i38 8.1 Assessment and immediate management of breathless patients on arrival in hospital
- i38 8.2 Differences in management in hospital compared with a prehospital setting
- i38 8.3 Which patients need oxygen therapy?
- i38 8.4 Which patients require blood gas measurements?
- i39 8.5 Can arterialised earlobe gases be used as a substitute of ABGs?
- i39 8.6 Should oxygen be prescribed at a fixed concentration or to achieve a target saturation?
- i39 8.7 What should be the target oxygen saturation range for patients receiving supplementary oxygen?
 - i39 8.7.1 Oxygen saturation target range for most patients
 - i40 8.7.2 Oxygen requirements of specific groups of patients
- i40 8.8 Importance of blood gas measurements in guiding oxygen therapy
- i40 8.9 What should be the initial choice of oxygen delivery system in hospital settings?
 - i40 8.9.1 Devices used in emergency oxygen therapy in hospitals
- i40 8.10 Recommended oxygen therapy for major medical emergencies and critical illness
 - i40 8.10.1 Cardiac arrest and other conditions requiring CPR
 - i41 8.10.2 Critically ill patients including major trauma, shock and major sepsis
 - i41 8.10.3 Drowning
 - i41 8.10.4 Anaphylaxis
 - i41 8.10.5 Major pulmonary haemorrhage or massive haemoptysis
 - i42 8.10.6 Epileptic fits
 - i42 8.10.7 Major head injury
 - i42 8.10.8 Carbon monoxide poisoning
- i42 8.11 Serious illnesses requiring moderate levels of supplemental oxygen if the patient is hypoxaemic

i43	8.11.1 Patients with acute onset of hypoxaemia of unknown cause with no pre-existing respiratory disorders or risk factors
i43	8.11.2 Acute asthma
i43	8.11.3 Pneumonia
i43	8.11.4 Lung cancer and other cancers with pulmonary involvement
i44	8.11.5 Deterioration of fibrotic lung conditions and other conditions involving parenchymal lung disease or alveolitis
i44	8.11.6 Pneumothorax
i44	8.11.7 Pleural effusion
i44	8.11.8 Pulmonary embolism
i44	8.11.9 Acute heart failure
i45	8.11.10 Breathlessness due to severe anaemia
i45	8.11.11 Sickle cell crisis
i45	8.12 Recommended oxygen therapy for patients who may be vulnerable to medium or high concentration of oxygen
i46	8.12.1 COPD exacerbations
i48	8.12.2 Exacerbation of CF
i48	8.12.3 Chronic musculoskeletal and neurological disorders
i48	8.12.4 Obesity-hypoventilation syndrome
i49	8.13 Common medical emergencies for which oxygen therapy is indicated only if hypoxaemia is present
i49	8.13.1 Acute myocardial infarction, suspected myocardial infarction and acute coronary syndromes
i50	8.13.2 Stroke
i51	8.13.3 Anxiety and hyperventilation or dysfunctional breathing
i51	8.13.4 Poisoning with substances other than carbon monoxide or cyanide
i52	8.13.5 Metabolic, endocrine and renal disorders
i52	8.13.6 Acute and subacute neuromuscular disorders producing respiratory muscle weakness
i52	8.13.7 Cluster headache
i52	8.14 Obstetric emergencies and labour
i54	8.15 Use of oxygen in postoperative and perioperative care, including PCA device use
i54	8.15.1 Oxygen use, pulse oximetry and the incidence of hypoxaemia in the postoperative period
i55	8.15.2 Patient-controlled analgesia
i55	8.15.3 The role of hyperoxaemia in reducing postoperative complications
i56	8.16 Use of oxygen during endoscopy and other procedures involving conscious sedation
i57	8.17 Use of oxygen in palliative care settings
i58	8.18 Use of helium–oxygen mixtures (Heliox)
i59	8.19 Use of CPAP
i59	8.19.1 Use of CPAP in perioperative care
i59	8.19.2 Use of CPAP in acute pulmonary oedema

Section 9: Emergency use of oxygen in ambulances, community and prehospital settings

i60	9.1 Pulse oximetry and availability of oxygen
i60	9.2 Clinical assessment by first responder(s) (GP, nurse or ambulance staff)
i60	9.3 Immediate management of hypoxaemic patients
i60	9.4 Patients with known COPD
i61	9.5 Patients who should be assumed to have COPD
i61	9.6 Other patients at risk of hypercapnic respiratory failure with respiratory acidosis
i61	9.7 Oxygen alert care and 24% or 28% Venturi masks in patients with COPD (and others at risk of respiratory acidosis) who have had an episode of hypercapnic respiratory failure
i62	9.8 Choice of devices in prehospital care
i62	9.9 Emergency use of oxygen in patient's home
i62	9.10 Use of oxygen by rescue services and other non-NHS first responders
i63	9.11 Use of nitrous oxide/oxygen mixtures (eg, Entonox)
i63	9.12 Use of oxygen in prehospital care for pregnant women
i62	Figure 8 Example of oxygen alert card

Section 10: Practical aspects of oxygen therapy

i63	10.1 Oxygen storage and provision and safety
i63	10.1.1 Cylinders
i64	10.1.2 Liquid oxygen
i64	10.1.3 Oxygen concentrators
i64	10.2 Patient delivery methods/interfaces
i64	10.2.1 High-concentration reservoir mask (non-rebreathing mask)
i64	10.2.2 Simple face mask
i64	10.2.3 Venturi mask
i66	10.2.4 Nasal cannulae
i67	10.2.5 High-flow humidified oxygen via nasal cannulae
i68	10.2.6 Tracheostomy mask
i68	10.2.7 Non-invasive ventilation
i68	10.3 Oxygen carriage and delivery during patient transport in ambulances
i68	10.3.1 Health and Safety Executive guidance for safe use of oxygen cylinders
i68	10.3.2 Oxygen use by UK ambulance services
i68	10.4 Oxygen carriage in other vehicles and in primary care settings and patients' homes
i68	10.4.1 Oxygen carriage in private cars (Health and Safety Executive guidance)
i69	10.4.2 Medical centres and primary care practices
i69	10.4.3 Emergency use of oxygen in the patient's home
i69	10.5 Oxygen delivery systems in hospitals
i69	10.5.1 Perioperative and postoperative care
i69	10.5.2 Emergency departments

i69	10.5.3 General wards and respiratory wards
i69	10.5.4 Devices used in emergency oxygen therapy
i70	10.5.5 Flow meters
i70	10.5.6 Oxygen tubing and oxygen wall outlets
i70	10.6 Use of humidified oxygen
i71	10.6.1 Rationale for use of humidified oxygen
i71	10.6.2 Use of bubble humidification systems
i71	10.6.3 Large volume nebulisation-based humidifiers
i71	10.7 Use of oxygen in patients with tracheostomy or laryngectomy
i72	10.8 Delivering oxygen to patients who require nebulized bronchodilator therapy
i72	10.8.1 Nebulised bronchodilator therapy in asthma
i72	10.8.2 Nebulised bronchodilator therapy for patients with COPD and other risk factors for hypercapnic respiratory failure
i73	10.9 Delivery of helium–oxygen mixtures (Heliox)
i73	10.10 Delivery of nitrous oxide/oxygen mixtures (eg, Entonox)
i73	10.11 Delivery of oxygen during procedures that may partially occlude the airway
i73	10.12 CPAP devices and indications
i64	Table 12 Examples of common oxygen cylinder sizes and capacities
i65	Table 13 Total gas flow rate from Venturi masks
i64	Figure 9 High-concentration reservoir mask
i64	Figure 10 Simple face mask
i65	Figure 11 A Venturi mask, range of concentrations, operation of Venturi valve
i65	Figure 11 B Suggested flow rates for Venturi masks and adjustment for high respiratory rate
i66	Figure 12 Oxygen saturation response to treatment
i67	Figure 13 Nasal cannulae
i67	Figure 14 High-flow humidified nasal cannulae, flow generator and humidifier system
i68	Figure 15 Tracheostomy mask
i70	Figure 16 Flow meter
i71	Figure 17 Air outlet cover
i72	Figure 18 Large volume nebulisation-based humidifier

Section 11: Prescription, administration and monitoring of oxygen therapy

i74	11.1 Safe prescription and administration of oxygen
i74	11.1.1 Legal status of medical oxygen: Does it need a prescription?
i74	11.1.2 Reasons to prescribe oxygen therapy
i74	11.1.3 Implementing an oxygen prescription policy
i75	11.1.4 Administration and monitoring of oxygen therapy
i75	11.1.5 Education of health professionals
i75	11.1.6 How to prescribe oxygen effectively
i77	11.2 Starting oxygen therapy

i77	11.3 Monitoring oxygen therapy
i77	11.3.1 Pulse oximeters
i77	11.3.2 Arterial or arterialised capillary blood gases
i77	11.3.3 Physiological monitoring: 'track and trigger' systems
i78	11.3.4 Monitoring during the first hour of oxygen therapy
i78	11.3.5 Subsequent monitoring
i78	11.3.6 When to increase oxygen therapy
i78	11.3.7 When to lower oxygen therapy
i76	Figure 19 Working example of oxygen section for hospital prescription charts

Section 12: Weaning and discontinuation of oxygen therapy

i78	12.1 How to discontinue oxygen therapy for stable patients
-----	--

Section 13: Outcomes and audit

i79	13.1 Audit
i79	13.2 Audit of compliance with guideline

Section 14: Dissemination and implementation of the guideline and education of healthcare professionals

i79	14.1 Dissemination
i79	14.2 Local guidelines
i79	14.3 Local oxygen policy
i79	14.4 Oxygen prescription chart
i79	14.5 Staff education
i79	14.6 Local champions
i79	14.7 Benefits of nationwide implementation

Areas requiring further research

References

Annex 1 Guideline group members

Online appendices

The below documents are available at <http://www.britthoracic.org.uk>

1. Search strategy
2. Evidence tables
3. Summary of guideline for hospital use
4. Example of local oxygen policy
5. Summary of guideline and flow charts for emergency oxygen use in ambulances, community and prehospital settings
6. Patient information sheet
7. Slides on emergency oxygen use for doctors
8. Slides on emergency oxygen use for nurses, midwives, pharmacists, physiotherapists and other practitioners who use oxygen
9. Key points for hospital managers and oxygen champions
10. Key points for primary care managers, clinical commissioning groups
11. Dissemination and implementation of the guideline